小智港股覆盤 | 2月17日
今日，港股三大指數集體上漲。截止收盤，恆生指數漲0.3%，報24792點。國企指數漲0.37%，報8711點。恆生科技指數漲0.82%，報5662點。市場約744只個股上漲，834只個股下跌。成交額突破1046.02億港幣，和昨天同期相比增長2.76%。南下資金淨流出7.24億港幣。
盤面上，CRO板塊全線走強。中國醫療集團漲超11%；藥明生物漲超6%；泰格醫藥、藥明康德、金斯瑞生物科技等多股漲超4%。藥明生物獲The Capital Group增持553.63萬股；泰格醫藥2月15日耗資163.48萬元回購1.66萬股A股；藥明康德2021年度歸屬於上市股東淨利潤50.97億元，同比增長72.19%；金斯瑞生物科技:子公司傳奇達成裏程碑事件，獲5000萬美元。
化學制品板塊大漲靠前。東嶽集團漲超13%；理文化工漲超6%；華寶國際漲超4%；世紀陽光漲超3%；阜豐集團漲超2%。東嶽集團拉昇10%，PVDF行業繼續擴產，公司業績大幅預喜。
食品零售板塊暴跌。高鑫零售跌超9%；易還財務投資跌超4%；亨泰、香港食品投資、大洋環球控股等多股跌超1%。麥格理下調高鑫零售目標價至4.05元，評級「跑贏大市」；易還財務投資前三季收入約7930萬港元，同比減少約16.08%。
建築建材板塊多數下跌。中國聯塑跌超4%；中國玻璃、佳辰控股等多股跌超2%。
無線電信板塊走弱。中國移動、和記電訊香港等多股跌超1%。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
